A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

Фаза 3 Завершено NCT06010004

Кратко

The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication. This study includes 3 periods as follows: * screening and lead-in period: up to 4 weeks * treatment period: 52 weeks, including 20 weeks of dose escalation, and * safety follow-up period: 2 weeks.

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Baseline to Week 54 · Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
• Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Uric Acid Lowering Trial in Youth Onset T2D — University of Colorado, Denver
• Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 — State University of New York at Buffalo
• Continuous Glucose Monitoring Following Hospital Discharge — Kathleen Dungan
• Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on I — University of Colorado, Denver

Все исследования